Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors.

Frontiers in immunology·2026

Same author

Establishment of <sup>68</sup>Ga-DOTA-Based Pretargeted Radioimmunodiagnosis.

Molecular pharmaceutics·2026

Same author

Pretargeted <sup>177</sup>Lu/<sup>225</sup>Ac combination therapy of colorectal cancer.

Theranostics·2026

Same author

T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.

Cell reports. Medicine·2026

Same author

Preclinical <sup>203/212</sup>Pb-DOTA-Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal Cancer Xenografts.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

International journal of cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibody therapies for solid tumors.

Dimiter V Tassev¹, Nai-Kong V Cheung

¹1Gerstner Sloan-Kettering Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Expert Opinion on Biological Therapy

|February 17, 2009

Summary

Monoclonal antibody therapies show modest anti-tumor responses in solid tumors but offer hope. Novel engineering and combination strategies are advancing antibody-based cancer treatments.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: Jun 25, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Area of Science:

Oncology
Immunotherapy
Drug Development

Background:

Cancer remains a leading cause of death, with significant economic burden.
Monoclonal antibodies (mAbs) are a promising therapeutic class for solid tumors.
Four mAbs are FDA-approved for solid tumors, with over 100 in clinical trials.

Purpose of the Study:

To summarize the clinical efficacy of FDA-approved and investigational monoclonal antibody therapies.
To provide an overview of the current landscape of antibody-based cancer treatments.

Main Methods:

Review of clinical efficacy data for approved and investigational monoclonal antibodies.
Summary of therapeutic strategies involving monoclonal antibodies in solid tumors.

Main Results:

Current anti-tumor responses for monoclonal antibody therapies have been modest.
Significant ongoing research and development in antibody engineering and combination therapies.

Conclusions:

Despite modest current responses, monoclonal antibodies hold promise for future cancer therapeutics.
Advancements in antibody engineering and combination strategies are key to improving efficacy in solid tumors.